Press Releases

November 18 2013

BIO commends the Senate for approving H.R. 3204, the Drug Quality and Security Act.

July 23 2012

Groups issue booklet to help biotechnology and pharmaceutical companies identify pipeline...

March 28 2012

H.R. 4274 will encourage continued investment in pediatric research.

May 25 2011

BIO commends Reps. Davis (D-Ca) and Schwartz (D-PA) for their continued efforts to extend the...

May 4 2011

BIO announces selection of Congressman Fred Upton (R-MI) as Legislator of the Year for 2010 -...

May 4 2011

BIO announced today its selection of Senator Bob Casey (D-PA) as Legislator of the Year for...

May 4 2011

BIO announces its selection of Representative David E. Price (D-NC) as Legislator of the Year...

May 4 2011

BIO announces its selection of Michael Capuano (D-MA) as Legislator of the Year for 2010 -...

May 3 2011

BIO along with the Juvenile Diabetes Research Foundation (JDRF) will feature a two-day...

April 7 2011

Today, the House Subcommittee on Healthcare and Technology will hold a hearing on The Creating...

March 16 2011

NIH Director Francis Collins, MD, PhD will share his insights on how ground-breaking biotech...

February 14 2011

Biotechnology Industry Organization (BIO) Industry Analysis and  BioMedTracker (BMT)...

January 26 2011

BIO's commends President Obama for highlighting the need to increase our nation...

January 12 2011

Experts chosen to speak on these panels represent leading clinical institutions, medical...

January 3 2011

The 2011 BIO International Convention will highlight the latest trends and the newest...

September 29 2010

BIO President and CEO Jim Greenwood released the following statement on action by the U.S....

May 4 2010

A new report issued by the Biotechnology Industry Organization underscores how biotechnology...

September 13 2013
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the “Draft Guidance for Industry on Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Pediatric Study Plans.” BIO commends FDA on the release of this Draft Guidance and shares the Agency’s commitment to ensure that safe and effective medicines are available for children.
August 26 2013
BIO fully supported the expansion and modernization of FDA’s Accelerated Approval pathway and the enactment of the new Breakthrough Therapy Designation Process under the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA, P.L. 112-144).
August 5 2013
BIO and its member companies appreciate FDA’s commitment to modernizing regulatory science and are committed to enhancing public health through advancements that fill knowledge gaps in drug development. To that end, BIO supports voluntary, responsible sharing of appropriately masked and de-identified safety and efficacy data as one potential way to develop new knowledge or new scientific insights. BIO member companies routinely publish clinical research results and collaborate with academic researchers, while both adhering to applicable privacy laws and regulations and protecting confidential commercial information.
July 10 2013
Therapeutic biologics are an opportunity to address unmet patient needs, drive innovation, and assist China's transformation into a knowledge-intensive economy.
June 19 2013
The TTIP represents a profoundly important opportunity to advance progress in these areas. The following comments represent BIO’s initial suggestions for the formulation of negotiating objectives relevant to biotechnology.  
April 7 2014
The EXPIRE Act would extend tax credits that expired at the end of 2013, including several of importance to the biotechnology industry.
November 18 2013
BIO commends the Senate for approving H.R. 3204, the Drug Quality and Security Act.
July 23 2012
Groups issue booklet to help biotechnology and pharmaceutical companies identify pipeline medicines with doping potential.
March 28 2012
H.R. 4274 will encourage continued investment in pediatric research.
May 25 2011
BIO commends Reps. Davis (D-Ca) and Schwartz (D-PA) for their continued efforts to extend the Qualifying Therapeutic Discovery Project Tax Credit.